Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC | MicrobiomeTrials← Back to trialsNCT04587128
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2020-10-19Est. Completion: 2029-10
Enrollment target: 34 participants Locations- University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Other microbiome trials you might be interested in
Advanced Solid Tumors
Immune therapies work with the body's immune system to treat a number of cancers. They work with T-cells, a type of whit…
Fullerton, United StatesCompleted May 11, 2026
Metastatic Colorectal Cancer
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mut…
Chandler, United StatesEst. completion Sep 25, 2028
Phase 1
Recruiting
CancerPDAC - Pancreatic Ductal AdenocarcinomaNSCLC (Non-small Cell Lung Cancer)CRC (Colorectal Cancer)Advanced Solid Tumors
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumor…
Orlando, United StatesEst. completion May 2029